Immatics: 'Buy' On 1st Half 2027 Catalyst, Potential Label Expansion For Uveal Melanoma

seekingalpha.com · 2026-08-25

Immatics is downgraded to Buy due to partial partnership termination and pivotal trial dependency. Click to learn more.